After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Nearly 200 medications, including several oncology treatments, are now available through the program.

In yet another move to pay down debt that matures in 2026, Walgreens Boots Alliance announced last night it would receive ...

The sale netted about $300 million for Walgreens and shrinks the company’s stake in Cencora to approximately 6%, down from 10 ...

Walgreens has sold more shares of drug distributor Cencora for proceeds of about $300 million in the latest effort to pay ...

Cencora is now targeting an 8% to 10% rise in revenue for the full fiscal year, a lift from its previous guidance for 7% to 9% growth. Sales are expected to rise 9% to 11% in its U.S. healthcare ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Cencora, Inc. (NYSE:COR) stands against the other stocks Jim Cramer ...

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Cencora, Inc.